X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs SUN PHARMA - Comparison Results

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA SUN PHARMA AJANTA PHARMA/
SUN PHARMA
 
P/E (TTM) x 19.8 45.9 43.1% View Chart
P/BV x 4.5 3.7 122.5% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 AJANTA PHARMA   SUN PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
SUN PHARMA
Mar-17
AJANTA PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,818842 215.9%   
Low Rs1,106572 193.2%   
Sales per share (Unadj.) Rs239.5131.6 181.9%  
Earnings per share (Unadj.) Rs52.832.7 161.4%  
Cash flow per share (Unadj.) Rs59.538.0 156.7%  
Dividends per share (Unadj.) Rs03.50 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs230.0152.7 150.6%  
Shares outstanding (eoy) m88.772,399.26 3.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.15.4 113.6%   
Avg P/E ratio x27.721.6 128.1%  
P/CF ratio (eoy) x24.618.6 131.9%  
Price / Book Value ratio x6.44.6 137.3%  
Dividend payout %010.7 0.0%   
Avg Mkt Cap Rs m129,7821,696,877 7.6%   
No. of employees `0006.817.5 38.8%   
Total wages/salary Rs m3,76549,023 7.7%   
Avg. sales/employee Rs Th3,128.418,028.3 17.4%   
Avg. wages/employee Rs Th554.02,798.8 19.8%   
Avg. net profit/employee Rs Th689.74,479.5 15.4%   
INCOME DATA
Net Sales Rs m21,258315,784 6.7%  
Other income Rs m2426,232 3.9%   
Total revenues Rs m21,499322,016 6.7%   
Gross profit Rs m6,584100,893 6.5%  
Depreciation Rs m59612,648 4.7%   
Interest Rs m43,998 0.1%   
Profit before tax Rs m6,22690,479 6.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,53912,116 12.7%   
Profit after tax Rs m4,68678,462 6.0%  
Gross profit margin %31.031.9 96.9%  
Effective tax rate %24.713.4 184.6%   
Net profit margin %22.024.8 88.7%  
BALANCE SHEET DATA
Current assets Rs m12,236329,537 3.7%   
Current liabilities Rs m3,461178,870 1.9%   
Net working cap to sales %41.347.7 86.5%  
Current ratio x3.51.8 191.9%  
Inventory Days Days6079 76.2%  
Debtors Days Days8483 101.5%  
Net fixed assets Rs m11,140204,766 5.4%   
Share capital Rs m1772,399 7.4%   
"Free" reserves Rs m20,237363,997 5.6%   
Net worth Rs m20,414366,397 5.6%   
Long term debt Rs m1014,361 0.1%   
Total assets Rs m24,486614,102 4.0%  
Interest coverage x1,519.423.6 6,429.8%   
Debt to equity ratio x00 1.3%  
Sales to assets ratio x0.90.5 168.8%   
Return on assets %19.213.4 142.7%  
Return on equity %23.021.4 107.2%  
Return on capital %30.524.8 122.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m11,66744,118 26.4%   
Fx outflow Rs m1,61624,484 6.6%   
Net fx Rs m10,05219,634 51.2%   
CASH FLOW
From Operations Rs m2,85470,822 4.0%  
From Investments Rs m-2,604-42,216 6.2%  
From Financial Activity Rs m-2-22,854 0.0%  
Net Cashflow Rs m2486,107 4.1%  

Share Holding

Indian Promoters % 73.8 63.7 115.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 5.1 30.2%  
FIIs % 7.6 23.0 33.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 8.3 204.8%  
Shareholders   20,968 133,026 15.8%  
Pledged promoter(s) holding % 4.4 0.5 828.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   STRIDES SHASUN LTD  ELDER PHARMA  ALEMBIC LTD  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Green; Metal Stocks Top Gainers(Closing)

After opening the day in green, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

SUN PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 12.0%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, SUN PHARMA has posted a net profit of Rs 16 bn (up 12.0% YoY). Sales on the other hand came in at Rs 70 bn (down 2.2% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jun 20, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS